---
title: "\"Performance\" Fudan-Zhangjiang reported a full-year loss of 157 million RMB, turning from profit to loss"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277347932.md"
description: "Fudan-Zhangjiang announced its performance report for the year 2025, achieving revenue of 686 million RMB (same below), a year-on-year decrease of 3.3%. The net loss attributable to shareholders was 157 million RMB, compared to a net profit of 39.73 million RMB in the previous year, turning from profit to loss; the loss per share was 0.15 RMB"
datetime: "2026-03-01T09:32:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277347932.md)
  - [en](https://longbridge.com/en/news/277347932.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277347932.md)
---

# "Performance" Fudan-Zhangjiang reported a full-year loss of 157 million RMB, turning from profit to loss

Fudan-Zhangjiang (01349.HK) announced its performance preliminary report for the fiscal year 2025, achieving revenue of 686 million RMB, a year-on-year decrease of 3.3%. The net loss attributable to shareholders was 157 million RMB, compared to a net profit of 39.73 million RMB in the previous year, turning from profit to loss; the loss per share was 0.15 RMB

### Related Stocks

- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [688505.CN](https://longbridge.com/en/quote/688505.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)

## Related News & Research

- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md)
- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)
- [Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds](https://longbridge.com/en/news/286487023.md)